NASDAQ:GLYC GlycoMimetics (GLYC) Stock Forecast, Price & News $1.50 -0.07 (-4.46%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.46▼$1.5750-Day Range$1.29▼$1.6552-Week Range$0.55▼$4.16Volume120,701 shsAverage Volume601,876 shsMarket Capitalization$96.48 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability GlycoMimetics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside433.3% Upside$8.00 Price TargetShort InterestHealthy1.59% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.86Based on 6 Articles This WeekInsider TradingAcquiring Shares$48,300 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector298th out of 973 stocksPharmaceutical Preparations Industry120th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, GlycoMimetics has a forecasted upside of 433.3% from its current price of $1.50.Amount of Analyst CoverageGlycoMimetics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.59% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 1.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 2.7 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,300.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions55.36% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to remain at ($0.61) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GlycoMimetics (NASDAQ:GLYC) StockGlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More GLYC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Stock News HeadlinesSeptember 26, 2023 | benzinga.comChief Medical Officer of GlycoMimetics Makes $90K BuySeptember 26, 2023 | marketwatch.comGlycoMimetics Shares Rise 12% After Medical Chief Buys SharesSeptember 29, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | finance.yahoo.comGlycoMimetics Insiders Placed Bullish Bets Worth US$890kSeptember 26, 2023 | americanbankingnews.comGlycoMimetics, Inc. (NASDAQ:GLYC) Insider Edwin Rock Acquires 35,000 Shares of StockSeptember 6, 2023 | finance.yahoo.comGlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687September 5, 2023 | finance.yahoo.comGlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceAugust 14, 2023 | msn.comGlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A ProblemSeptember 29, 2023 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! August 3, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on GlycoMimetics (GLYC)August 2, 2023 | washingtonpost.comGlycoMimetics: Q2 Earnings SnapshotAugust 2, 2023 | msn.comGlycoMimetics Non-GAAP EPS of -$0.13 beats by $0.04August 2, 2023 | finance.yahoo.comGlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023August 1, 2023 | msn.comForte Biosciences closes $25M financing, to advance FB-102 in 2024August 1, 2023 | markets.businessinsider.comGlycoMimetics earnings preview: what Wall Street is expectingJuly 19, 2023 | finance.yahoo.comGlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023June 26, 2023 | seekingalpha.comGlycoMimetics joins Russell Microcap indexJune 26, 2023 | finance.yahoo.comGlycoMimetics Announces Its Addition to the Russell Microcap® IndexJune 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on GlycoMimetics (GLYC)June 15, 2023 | finance.yahoo.comGlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid LeukemiaJune 12, 2023 | finance.yahoo.comWe Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth CarefullyMay 31, 2023 | finance.yahoo.comGlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare ConferenceMay 30, 2023 | msn.comGlycoMimetics: Insider Buying Continues, And Chart Looks HealthyMay 16, 2023 | finance.yahoo.comretail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last weekMay 12, 2023 | seekingalpha.comGlycoMimetics: An Asymmetric Opportunity That Could Change HematologyMay 4, 2023 | finance.yahoo.comQ1 2023 GlycoMimetics Inc Earnings CallMay 3, 2023 | finance.yahoo.comGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023See More Headlines Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Company Calendar Last Earnings8/02/2023Today9/29/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+433.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,690,000.00 Net MarginsN/A Pretax Margin-56,526.67% Return on Equity-71.89% Return on Assets-62.70% Debt Debt-to-Equity RatioN/A Current Ratio9.19 Quick Ratio9.19 Sales & Book Value Annual Sales$80,000.00 Price / Sales1,206.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book1.83Miscellaneous Outstanding Shares64,320,000Free Float59,171,000Market Cap$96.48 million OptionableOptionable Beta2.05 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Harout Semerjian (Age 53)CEO, Pres & Director Comp: $1.1MMs. Rachel K. King (Age 64)Co-Founder & Director Comp: $226.43kMr. Brian M. Hahn (Age 49)Sr. VP & CFO Comp: $748.27kMs. Stephanie R. Irish CPA (Age 52)VP of Accounting Mr. Christian B. Dinneen-LongGen. Counsel & Company Sec.Mr. Bruce Johnson (Age 55)Sr. VP & Chief Commercial Officer Dr. Edwin Rock M.D. (Age 62)Ph.D., Sr. VP & Chief Medical Officer Mr. Chinmaya Rath (Age 47)Sr. VP & Chief Bus. Officer More ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBAtossa TherapeuticsNASDAQ:ATOSImmunomeNASDAQ:IMNMRelmada TherapeuticsNASDAQ:RLMDBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInsiders & InstitutionsEdwin RockBought 35,000 shares on 9/21/2023Total: $48,300.00 ($1.38/share)Wolverine Trading LLCSold 15,000 shares on 8/23/2023Ownership: 0.000%Affinity Asset Advisors LLCSold 300,000 shares on 8/21/2023Ownership: 0.000%Goldman Sachs Group Inc.Sold 118,160 shares on 8/15/2023Ownership: 1.218%XTX Topco LtdBought 29,998 shares on 8/15/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions GLYC Stock - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares. View GLYC analyst ratings or view top-rated stocks. What is GlycoMimetics' stock price forecast for 2023? 1 analysts have issued 12-month price targets for GlycoMimetics' shares. Their GLYC share price forecasts range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 433.3% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts. How have GLYC shares performed in 2023? GlycoMimetics' stock was trading at $3.03 on January 1st, 2023. Since then, GLYC shares have decreased by 50.5% and is now trading at $1.50. View the best growth stocks for 2023 here. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our GLYC earnings forecast. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). What is GlycoMimetics' stock symbol? GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC." How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GlycoMimetics' stock price today? One share of GLYC stock can currently be purchased for approximately $1.50. How much money does GlycoMimetics make? GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $96.48 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-46,690,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How can I contact GlycoMimetics? GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137. This page (NASDAQ:GLYC) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.